KURE - KraneShares MSCI All China Health Care Index ETF
| Assets | $221.48M |
| NAV | $39.55 |
| Expense Ratio | 0.65% |
| PE Ratio | 36.58 |
| Beta (5Y) | 0.61 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Dec 27, 2019 |
| 1-Year Return | - |
| Trading Day | April 21 |
| Last Price | $40.33 |
| Previous Close | $39.66 |
| Change ($) | 0.67 |
| Change (%) | 1.69% |
| Day's Open | 40.00 |
| Day's Range | 39.87 - 40.49 |
| Day's Volume | 70,783 |
| 52-Week Range | 24.80 - 47.69 |
Fund Description
The investment seeks to provide investment results that, before fees and expenses, track the price and yield performance of the MSCI China All Shares Health Care 10/40 Index (the underlying index). The fund will invest at least 80% of its total assets in components of the underlying index, depositary receipts, including American depositary receipts, representing such components and securities underlying depositary receipts in the underlying index. The underlying index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the healthcare sector. The fund is non-diversified.
| Asset Class Equity | Inception Date Feb 1, 2018 |
| Exchange NYSEARCA | Ticker Symbol KURE |
| Index Tracked MSCI China All Shares Health Care 10/40 Index | |
Top 10 Holdings
43.98% of assets| Name | Symbol | Weight |
|---|---|---|
| WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S | 2269.HK | 9.08% |
| Jiangsu Hengrui Medicine Co Ltd | 600276.SS | 6.07% |
| Shenzhen Mindray Bio-Medical Electronics Co Ltd | 300760.SZ | 5.21% |
| BeiGene | BGNE | 3.96% |
| Wuxi AppTec Co Ltd Class A | 603259.SS | 3.92% |
| Chongqing Zhifei Biological Products Co Ltd | 300122.SZ | 3.61% |
| Alibaba Health Information Technology Ltd | 241.HK | 3.14% |
| Aier Eye Hospital Group Co Ltd | 300015.SZ | 3.05% |
| CSPC Pharmaceutical Group Ltd | 1093.HK | 3.05% |
| Sino Biopharmaceutical Ltd | 1177.HK | 2.89% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 29, 2020 | $0.00 | Dec 31, 2020 |
| Dec 27, 2019 | $0.057 | Dec 31, 2019 |
| Dec 26, 2018 | $0.039 | Dec 28, 2018 |
In the United States, healthcare is a dynamic sector home to defensive value stocks, disruptive growth names, and plenty of in-between. China offers a comparable level of healthcare dynamism, which inve...
The best pharmaceutical ETFs for Q2 2021 are KURE, MJJ, and POTX.
The best healthcare ETFs for Q1 2021 are ARKG, PTH, and KURE.
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
Chinese stocks have biggest gains in 3 months
Yahoo Finance's Tom Belger reports on the latest stock news from China and Europe.
The best healthcare ETFs for Q4 2020 are ARKG, KURE, and PTH.
The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.
Sector ETFs and industry funds are different. The 11 sectors addressed in the S&P 500 are as follows (in order of weight in the index): technology, healthcare, consumer discretionary, communication serv...
The Chinese economy returned to growth in the second quarter of 2020. This along with PBOC's targeted policy easing and China's solid tech industry make China investing winners in the recent trading ses...
In theory, blaming the emerging markets malaise on China because the country was the initial epicenter of the coronavirus appears to make sense. However, that argument doesn't hold water because the MSC...
While most the countries' stocks have been beaten down badly in the pandemic, some still managed to trade in green for the first half of the year.
The fund hit a 52-week high lately. Can this go further higher?
The best pharmaceutical ETFs for Q3 2020 are KURE, XPH, and PPH.
The best Healthcare ETFs for Q3 2020 are ARKG, KURE, and PTH.
Healthcare stocks and ETFs are outperforming the broader market this year, but as the KraneShares MSCI All China Health Care Indes ETF (KURE) proves, that theme isn’t confined to the U.S. KURE invests i...
As stock markets rallied higher Monday after consolidation and pullback over the last couple of days, one ETF was making some considerable moves on the foreign asset front as well.
These international ETFs have outperformed the S&P 500 in the first quarter.
Over the past several weeks, China stocks and ETFs have been surprisingly sturdy as the coronavirus appears to be contained there at least for.
These sector ETFs gained or lost the least in the coronavirus-induced rout in February.
There has been plenty of talk about how China ETFs may perform when the COVID-19 virus is officially put to rest, but there are some examples of some of those ETFs displaying strength in a challenging e...
ETF Trends CEO Tom Lydon discussed the KraneShares MSCI All China Health Care Indes ETF (KURE) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show.
The best pharmaceutical ETFs for Q1 2020 are KURE, CHIH, and CHNA.
The best Healthcare ETFs for Q1 2020 are BBC, SBIO, and KURE.
It's not unusual for an emerging markets exchange traded fund to use exclusionary tactics. What is unusual is when an emerging market ETF offering access to multiple developing economies excludes China,...